Top Markets
#1 EXOD EXOD +56.80%
#2 Cysic Cysic +14.17%
#3 Biconomy Biconomy +13.82%
#4 Fabric Protocol Fabric Protocol +7.20%
#5 Collect on Fanable Collect on Fanable +4.30%
#6 Cap Cap +3.90%
#7 Dual Dual +3.58%
#8 Catizen Catizen +3.50%
#9 Figure Heloc Figure Heloc +3.49%
#10 Avantis Avantis +3.32%
Coin of the day
EXOD EXOD
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Evgen Pharma plc Evgen Pharma plc

Evgen Pharma plc

EVG
Rangering i aksjer #38016
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates... Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Aksjekurs
$0.00953895
Sist synkronisert: 2024-05-22
Markedsverdi
$1.28M
Endring (1 dag)
0.06%
Endring (1 år)
0.00%
Land
GB
Handel Evgen Pharma plc (EVG)

Kategori

Healthcare
Inntekter for Evgen Pharma plc (EVG)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Evgen Pharma plc er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Evgen Pharma plc fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE